FDA Investigator Edward D Harris

Edward D Harris has conducted inspections on 306 sites in 2 countries as of 23 Oct 2013. See below for a list of the FDA enforcement documents resulting from those inspections.

Investigator Details

Number of Inspected Sites:
306
Last Inspection Date:
23 Oct 2013
Investigator Role:
FDA Investigator
Redica ID:
Countries of Inspections:
United States of America, United Kingdom of Great Britain and Northern Ireland
FDA Investigators that have inspected at least one site in common with Edward D Harris:
Abby M Miller, Abha R Bommireddi, Alan D Grupe, Alexander M Kay, Amanda E Lewin, PhD, Amanda N Schaupp, Anastasia I Onuorah, Andrew K Haack, PhD, Andrew S Johnson, Angel K Sandhu, Anh Trinh T Nguyen, Anthony E Keller, RPh, Ashar P Parikh, Ava M Bowman, Barbara T Carmichael, Brenda K Alford, Brenda L Reihing, Bruce R Burrell, Bryan Baker, Bryce A May, Camille Bennett Hoffman, Capri R Woolridge, Carl A Anderson, Carl Lee, Carol F Robinson, Catherine J Laufmann, Ce'nedra M Martin, Celeta S Coves, Celia L Silverstein, Charles A Snipes, PhD, Chloe Anne Leong, Christopher R Czajka, Colleen M Jones, Connie P Rezendes, Cynthia L Gorveatt, Dan G Eisenbrey, Daniel C Geffin, Darla J Christopher, Darlene B Almogela, David A Lum, David J Hajduk, David L Hunsaker, Deborah K Richardson, Deborah Kleinfeld, Dellarese L Herbert, Dena L Jacobs, Dennis R Hudson, Dianna D Wardlow Dotter, Dolores E Price, Donald B Mckechnie, Donald W Jehn, Douglas C Kovacs, Dr. Zhou Chen (nmi), MD PhD, Dustin P Tran, Dylan D Yao, MD, PhD, Edna J Hidalgo, Edward D Vains, Elizabeth S Howell, Emil P Wang, JD, Emily B Camire, Erica R Pomeroy, Frank P Bianco, Garrad R Poole, George F Long, Gerald N Mcgirl, DDS, Gina C Collins, Glen E Harelson, Gloria J Baca, MS, Hanna L Potter, Heika R Tait, Helen J Hamaoka, Herbert E Arden, Himanshu Gupta, PhD, Hugh A Grimoldby, Humberto Z Gomez, Ingrid A Zambrana, James A Barreto, James S Cartwright, Jamie L Port, Janice R Small, Jason D Werne, Jason T Lovelady, Jeanne M Weishaar, Jeffrey M Watson, Jeffrey W Shrifter, DPM, Jennifer S King, Jessica L Walters Moell, Jessie J Deloach, Jinkee Mvila Binayug, Joan T Briones, John A Iwen, John A Liu, Jonathan T Little, Joseph M Willems, Joseph Tibay, Juan A Morales, Jude C Dikes, Julian C Hanson, Kaarin M Slotte, Kara A Scheibner, PhD, Karen J Bak, Karla J Gibler, Kathleen B Swat, Kathryn A Krentz, Kawshalya Pathiraja, Keishla M Arroyo Lopez, Kelly D Moore, Kenneth G Klobus, Kimberly L Anderson, Kip J Hanks, Kristina M Phelps, Lance Mde Souza, MBA, Laura Kathryn, Laverne Puckett, LCDR Ismael Olvera, IV, LCDR Wilfred A Darang, Leslie W Gilbert, Lija V Fellows, Linda Linh N Adams, Lisa M Althar, Lori J Silverstein, Lorna F Jones, Lourdes Andujar, Mabel M Lee, Macropolk, Maida Henesian (NMI), Marc A Jackson, Jr, Maridali Deleon Torres, Marie K Kinkade, Mark E Baldwin, Mark E Imsland, Mark E Moen, Mark Harris, Mark S Crippen, Mark W Babbitt, Marsha L Mccauley, Mary Ewilkerson Brinsko, Matthew K Wong, Melissa D Kalik, Melkamu Getie Kebtie, PhD, Mihaly S Ligmond, Mikel T Wright, Nancy E Byerly, Nancy E Doyle, Nianna C Burns, Nympha V Florendo, Paul F Rader, Paul M Chefor, Paul M Kawamoto, Paula A Trost, Peter Kessler, PhD, Peter T Regan, Prabhu P Raju, Randall P Zielinski, Randy L Elsberry, Rebecca A Sletner, Rebecca T Davis, Richard G Runyon, Richard Heath Coats, Richard L Bartlett, Richard T Riggie, Robert D Tollefsen, Robles, Rocco C Black, Roger D Gawne, Ruth A Williams, Ryan Raffaelli, Sam Pepe, Sandra S Saniga, Sarah J Cullen, Scott A Nabe, Scott W Fox, Seema S Singh, Seyyida Saterfield, Sharon L Shane, Shelagh D Schopen, Shelley H Beausoleil, Sherri J Jackson, Stephen R Souza, Stuart W Russell, Sunitha K Rajaram, PhD, Suzette W Peng, Terrence Gee, Thea C Grome, Tiffany Chao, Timothy C Grome, Travelle D Mason, Travis S Bradley, Vanessa Y Gelsey, PhD, Vanessa Y Jacobs, Victoria V Bot, William J Foust, William J Weis, Willis L Hicks, Xiaohan Cai, PhD, Young M Yoon, Yvonne M Larsen

Edward D Harris's Documents

Publish Date Document Type Title
July, 2001 FDA 483 Biomat USA, Inc. - Form 483, 2001-07-03
August, 2013 EIR Biomat USA Inc - EIR, 2013-08-08
January, 2013 EIR Daniel L. Peterson, M.D. - EIR, 2013-01-09
October, 2009 FDA 483 Charles River Laboratories, Inc - Form 483, 2009-10-23
June, 2001 EIR Charles River Laboratories, Inc - EIR, 2001-06-07
September, 2001 FDA 483 Bloodworks - Form 483, 2001-09-10
July, 2004 FDA 483 Charles River Laboratories, Inc - Form 483, 2004-07-08
May, 2007 FDA 483 Charles River Laboratories, Inc - Form 483, 2007-05-23
June, 2000 EIR Charles River Laboratories, Inc - EIR, 2000-06-16
July, 2012 EIR Charles River Laboratories, Inc - EIR, 2012-07-25
July, 2004 EIR Charles River Laboratories, Inc - EIR, 2004-07-08
May, 2000 FDA 483 Pharmacology Research Corp - Form 483, 2000-05-18
February, 2001 FDA 483 Biomat USA, Inc. - Form 483, 2001-02-14
June, 2001 EIR Seattle Cancer Care Alliance - EIR, 2001-06-01
February, 2001 EIR Biomat USA, Inc. - EIR, 2001-02-14
May, 2000 EIR ALTINSAN, SAIDE MD - EIR, 2000-05-18
February, 2001 FDA 483 Response Biomat USA, Inc. - Form 483R, 2001-02-21
June, 2000 FDA 483 M/V Columbia Queen - Form 483, 2000-06-02
May, 2000 EIR Pharmacology Research Corp - EIR, 2001-03-08
July, 2001 EIR Biomat USA, Inc. - EIR, 2001-07-03
April, 2004 EIR Eli Lilly And Co. Limited - EIR, 2007-06-21
September, 2003 EIR Starbucks Manufacturing Corp - EIR, 2003-09-25
January, 2013 FDA 483 Daniel L. Peterson, M.D. - Form 483, 2013-01-09
June, 2000 EIR M/V Columbia Queen - EIR, 2000-06-02
December, 2002 FDA 483 Charles River Laboratories, Inc - Form 483, 2002-12-12
December, 2002 EIR Charles River Laboratories, Inc - EIR, 2002-12-12
July, 2006 EIR TRP Company, Inc - EIR, 2006-07-25
November, 2000 FDA 483 Biomat Usa, Inc. - Form 483, 2000-11-17

Experience Redica Systems’ NEW investigator profiles and dashboards

Redica Systems customers get access to over 1,400 FDA Investigator profiles, containing powerful analysis like:

  • Total inspections conducted
  • 483 rate
  • OAI rate
  • Warning Letter rate
  • Inspections by Industry, Scope, and Inspection Reason
  • And much more

Investigator Profiles are not sold as on-demand documents. If you’d like to see one, fill out the form below to connect with our Sales Team and get it in your inbox as little as 24 hours.

FDA Investigator Profile Icon

Talk to sales to access our investigator profiles

Loading...

Investigator Profiles Are Just the Tip of the Iceberg

Becoming a Redica Systems customer not only provides you with unlimited access to profiles similar to the one above for every current and former FDA Investigator, but also grants you access to:

Inspection Intelligence

  • Pre-Approval Inspection (PAI) trends
  • The ability to filter nearly any FDA enforcement action by GxP labels like GMP, GCP, etc.
  • Latest 483s: see what the trends are across all FDA Investigators
  • CFR Heatmap: Citations aggregated by Subpart by Year

Vendor Intelligence

  • Full inspection histories for your vendors down to the specific site level
  • All of the functionality mentioned above but isolated to just your vendors

Regulatory Intelligence

  • Zero in on the trends for a specific agency/regulator (ex. FDA, MHRA, EMA, Health Canada)
  • All the latest "Signals" from agencies around the world, segmented by Country, Type (ex. Guidance, Decree...), Category (ex. Rules/Regulations/Guidance, News, Reports...), Theme (ex. Cell and Gene Therapy, AI...), and more